Zensar Technologies’ shares surged nearly 10% after reporting strong Q3FY25 results, with a 10.1% YoY revenue growth to Rs 1,325.6 crore. However, profitability declined 2.7% YoY to Rs 159.8 crore. Operating revenue grew 8.6% YoY, with a PAT margin of 12%. The stock has gained 53.5% over the past year.
Nifty Pharma, 4 others hit 52-week high since Iran war while Nifty fell 7%. Will the form continue?
Despite a challenging market backdrop fueled by geopolitical tensions and foreign fund outflows, five Indian sectors—Pharma, Energy, Defence, Capital Markets, and Metals—are showing remarkable strength.
May 25, 2026